Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-Label Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)

NCT03439293 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT03439293
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03439293 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-Label Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)
Lead sponsor
Takeda
Phase
Phase 2
Overall status
Completed
Start date
March 13, 2018
Completion date
June 26, 2023
Enrollment
61 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma